Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1-year price objectives for Ironwood Pharmaceuticals' shares. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 38.5% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.

Ironwood Pharmaceuticals' stock was trading at $11.66 at the start of the year. Since then, IRWD shares have decreased by 10.2% and is now trading at $10.47.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our IRWD earnings forecast.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its earnings results on Thursday, August, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.10. The biotechnology company earned $97.23 million during the quarter, compared to analysts' expectations of $103.51 million. Ironwood Pharmaceuticals had a net margin of 41.65% and a trailing twelve-month return on equity of 31.01%. The business's revenue for the quarter was down 6.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 EPS.

Ironwood Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$430.00 million, compared to the consensus revenue estimate of $428.80 million.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRWD stock can currently be purchased for approximately $10.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.60 billion and generates $413.75 million in revenue each year. The biotechnology company earns $528.45 million in net income (profit) each year or $1.01 on an earnings per share basis.

The company employs 219 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.